CONSOLIDATED STATEMENT OF OPERATIONS - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Revenues:
Revenues	$ 110,701	$ 118,192	$ 102,428
Operating expenses:
Research and development	230,819	180,647	145,922
General and administrative	63,219	67,097	61,686
Total operating expenses	294,038	247,744	207,608
Loss from operations	(183,337)	(129,552)	(105,180)
Interest and other income, net	5,346	8,775	9,761
Loss before income taxes	(177,991)	(120,777)	(95,419)
Income tax expense	306	345	0
Net loss	(178,297)	(121,122)	(95,419)
Net loss attributable to non-controlling interest	(11)	(126)	(233)
Net loss attributable to Sangamo Therapeutics, Inc. stockholders	$ (178,286)	$ (120,996)	$ (95,186)
Basic net loss per share attributable to Sangamo Therapeutics, Inc. stockholders (in dollars per share)	$ (1.23)	$ (0.90)	$ (0.85)
Diluted net loss per share attributable to Sangamo Therapeutics, Inc. stockholders (in dollars per share)	$ (1.23)	$ (0.90)	$ (0.85)
Shares used in computing basic net loss per share attributable to Sangamo Therapeutics, Inc. stockholders (in shares)	144,568	134,449	112,114
Shares used in computing diluted net loss per share attributable to Sangamo Therapeutics, Inc. stockholders (in shares)	144,568	134,449	112,114